Home > Research > Publications & Outputs > GSK3
View graph of relations

GSK3: a key target for the development of novel treatments for type 2 diabetes mellitus and Alzheimer disease

Research output: Contribution to Journal/MagazineJournal articlepeer-review

Published

Standard

GSK3: a key target for the development of novel treatments for type 2 diabetes mellitus and Alzheimer disease. / Gao, Chong; Hölscher, Christian; Liu, Yueze et al.
In: Reviews in the Neurosciences, Vol. 23, No. 1, 02.2012, p. 1-11.

Research output: Contribution to Journal/MagazineJournal articlepeer-review

Harvard

APA

Vancouver

Gao C, Hölscher C, Liu Y, Li L. GSK3: a key target for the development of novel treatments for type 2 diabetes mellitus and Alzheimer disease. Reviews in the Neurosciences. 2012 Feb;23(1):1-11. Epub 2011 Dec 21. doi: 10.1515/rns.2011.061

Author

Gao, Chong ; Hölscher, Christian ; Liu, Yueze et al. / GSK3 : a key target for the development of novel treatments for type 2 diabetes mellitus and Alzheimer disease. In: Reviews in the Neurosciences. 2012 ; Vol. 23, No. 1. pp. 1-11.

Bibtex

@article{e467f78f07f2411f8054b4b66dad7315,
title = "GSK3: a key target for the development of novel treatments for type 2 diabetes mellitus and Alzheimer disease",
abstract = "As a constitutively active kinase, glycogen synthase kinase 3 (GSK3) is a kinase which regulates body metabolism by phosphorylation of glycogen synthase (GS) and other substrates. Considerable evidence suggests that GSK3 is involved in the common pathology underlying Alzheimer's disease (AD) and type 2 diabetes mellitus (T2DM). The overexpression or overactivation of GSK3 could induce a series of pathological changes, most of which are hallmarks of AD and T2DM. Therefore, GSK3 could be a novel target to treat these two age-dependent diseases. The inhibition of this kinase can prevent the aggregation of β-amyloid (Aβ) and hyperphosphorylation of tau protein. GSK3 inhibition can also be a promising strategy to ameliorate neurodegenerative developments. Its potential association with memory formation has been shown in electrophysiological and behavioral experiments. The neuroprotective effects of novel drugs developed to treat T2DM, glucagon-like peptide 1 (GLP-1) and its long-lasting analogs, have a possible link to GSK3 modification. Recent investigations of the interaction between the phosphatidylinositol 3 kinase (PI3K) signaling pathway and the protective effect of novel GPL-1 receptor agonist geniposide on PC12 cells support this theory.",
keywords = "Alzheimer Disease, Animals, Diabetes Mellitus, Type 2, Enzyme Inhibitors, Glycogen Synthase Kinase 3, Humans, Signal Transduction",
author = "Chong Gao and Christian H{\"o}lscher and Yueze Liu and Lin Li",
year = "2012",
month = feb,
doi = "10.1515/rns.2011.061",
language = "English",
volume = "23",
pages = "1--11",
journal = "Reviews in the Neurosciences",
issn = "0334-1763",
publisher = "WALTER DE GRUYTER GMBH",
number = "1",

}

RIS

TY - JOUR

T1 - GSK3

T2 - a key target for the development of novel treatments for type 2 diabetes mellitus and Alzheimer disease

AU - Gao, Chong

AU - Hölscher, Christian

AU - Liu, Yueze

AU - Li, Lin

PY - 2012/2

Y1 - 2012/2

N2 - As a constitutively active kinase, glycogen synthase kinase 3 (GSK3) is a kinase which regulates body metabolism by phosphorylation of glycogen synthase (GS) and other substrates. Considerable evidence suggests that GSK3 is involved in the common pathology underlying Alzheimer's disease (AD) and type 2 diabetes mellitus (T2DM). The overexpression or overactivation of GSK3 could induce a series of pathological changes, most of which are hallmarks of AD and T2DM. Therefore, GSK3 could be a novel target to treat these two age-dependent diseases. The inhibition of this kinase can prevent the aggregation of β-amyloid (Aβ) and hyperphosphorylation of tau protein. GSK3 inhibition can also be a promising strategy to ameliorate neurodegenerative developments. Its potential association with memory formation has been shown in electrophysiological and behavioral experiments. The neuroprotective effects of novel drugs developed to treat T2DM, glucagon-like peptide 1 (GLP-1) and its long-lasting analogs, have a possible link to GSK3 modification. Recent investigations of the interaction between the phosphatidylinositol 3 kinase (PI3K) signaling pathway and the protective effect of novel GPL-1 receptor agonist geniposide on PC12 cells support this theory.

AB - As a constitutively active kinase, glycogen synthase kinase 3 (GSK3) is a kinase which regulates body metabolism by phosphorylation of glycogen synthase (GS) and other substrates. Considerable evidence suggests that GSK3 is involved in the common pathology underlying Alzheimer's disease (AD) and type 2 diabetes mellitus (T2DM). The overexpression or overactivation of GSK3 could induce a series of pathological changes, most of which are hallmarks of AD and T2DM. Therefore, GSK3 could be a novel target to treat these two age-dependent diseases. The inhibition of this kinase can prevent the aggregation of β-amyloid (Aβ) and hyperphosphorylation of tau protein. GSK3 inhibition can also be a promising strategy to ameliorate neurodegenerative developments. Its potential association with memory formation has been shown in electrophysiological and behavioral experiments. The neuroprotective effects of novel drugs developed to treat T2DM, glucagon-like peptide 1 (GLP-1) and its long-lasting analogs, have a possible link to GSK3 modification. Recent investigations of the interaction between the phosphatidylinositol 3 kinase (PI3K) signaling pathway and the protective effect of novel GPL-1 receptor agonist geniposide on PC12 cells support this theory.

KW - Alzheimer Disease

KW - Animals

KW - Diabetes Mellitus, Type 2

KW - Enzyme Inhibitors

KW - Glycogen Synthase Kinase 3

KW - Humans

KW - Signal Transduction

U2 - 10.1515/rns.2011.061

DO - 10.1515/rns.2011.061

M3 - Journal article

C2 - 22718609

VL - 23

SP - 1

EP - 11

JO - Reviews in the Neurosciences

JF - Reviews in the Neurosciences

SN - 0334-1763

IS - 1

ER -